Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC Meeting Abstract
| Authors: | Burns, T. F.; Dragnev, K. H.; Fujiwara, Y.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P. A.; Italiano, A.; Heist, R. S.; Han, J. Y.; Deming, D. A.; Spira, A. I.; Sabari, J. K.; Chisamore, M. J.; Fink, A. A.; Chen, A.; Willard, M. D.; Oxnard, G. R.; Ammakkanavar, N. R. |
| Abstract Title: | Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557402009 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.8510 |
| Notes: | Meeting Abstract: 8510 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work